PLA2G7/PAF-AH/Lp-PLA2 Antibody [Unconjugated]

Western blot shows lysates of human plasma. PVDF membrane was probed with 1 µg/mL of Goat Anti-Human PLA2G7/PAF-AH/Lp-PLA2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF5106) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF019). A specific band was detected for PLA2G7/PAF-AH/Lp-PLA2 at approximately 29 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 8.

Simple Western lane view shows human plasma, loaded at 1:10 dilution. A specific band was detected for PLA2G7/PAF‑AH/Lp‑PLA2 at approximately 33 kDa (as indicated) using 10 µg/mL of Goat Anti-Human PLA2G7/PAF‑AH/Lp‑PLA2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF5106) followed by 1:50 dilution of HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF109). This experiment was conducted under reducing conditions and using the12-230 kDa separation system.

• Reactivity: Hu
• Applications: WB, Simple Western, IP
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

PLA2G7/PAF-AH/Lp-PLA2 Antibody [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant human PLA2G7/PAF-AH/Lp-PLA2
  Met33-Asn441
  Accession # AAH38452
• Specificity: Detects human PLA2G7/PAF-AH/Lp-PLA2 in direct ELISAs and Western blots. In direct ELISAs, less than 1% cross-reactivity with recombinant human (rh) PLA2G-2A, recombinant mouse PLA2G-2A, and rhPLA2G-1B is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: PLA2G7
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Immunoprecipitation 25 ug/mL
  • Simple Western 10 ug/mL
  • Western Blot 1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for PLA2G7/PAF-AH/Lp-PLA2 Antibody [Unconjugated]

• 2-acetyl-1-alkylglycerophosphocholine esterase
• EC 3.1.1
• EC 3.1.1.47,1-alkyl-2-acetylglycerophosphocholine esterase
• Group-VIIA phospholipase A2
• gVIIA-PLA2
• LDL-associated phospholipase A2
• LDL-PLA(2)
• LDL-PLA2
• lipoprotein-associated phospholipase A2
• LpPLA2
• Lp-PLA2
• PAF acetylhydrolase
• PAF-AH
• PAFAHPAF 2-acylhydrolase
• phospholipase A2, group VII (platelet-activating factor acetylhydrolase
• PLA2G7
• plasma)
• platelet-activating factor acetylhydrolase

Background

Secretory phopholipase A₂ is an enzyme that hydrolyses the Sn-2 ester bond of phospholipids, generating free fatty acids and lysophospholipids (1‑3). Most secretory PLA₂s are stored in cytoplasmic granules and are released in the extracellular environment on appropriate cell activation. Thus, they are present at higher concentration in the plasma and biologic fluids of patients with systemic inflammatory, autoimmune, or allergic disease, such as acute pancreatitis, rheumatoid arthritis, bronchial asthma, and allergic rhinitis. Also known as Lp-PLA2, PLA2G-VII is a plasma enzyme bound to lipoproteins: 80% bound to LDL, 15%‑20% to HDL, and the remainder to VLDL (4‑6). It is produced in major by mature macrophages and activated platelets. In contrast to other classical sPLA₂s, PLA2G‑VII has poor specificity toward Sn-2 long chain fatty acids, unless heavily oxidized, and undergoes the catalysis of its substrates in the aqueous phase rather than at the interfacial surface of lipids. Thus, it has high specificity for water-soluble phospholipids in plasma including oxidatively‑modified phospholipids and platelet-activating factor (PAF). Because of the latter activity, it is also known as PAF acetylhydrolase (PAF-AH). Lack of human PLA2G‑VII is related to a higher risk for stroke and heart disease.

1. Webb, N. R. (2005) Cur. Opin. Lipid. 16:341.
2. Triggiani, M. et al. (2005) J. Allergy Clin. Immunol. 116:1000.
3. Murakami, M. and Kudo, I. (2004) Biol. Pharm. Bull. 27:1158.
4. Caslake, M. J. and Packard C. J. (2005) Nat. Clin. Prac. Cardiovasc. Med. 2:529.
5. Karabina, S.-A., and Ninio, E. (2006) Biochim. Biophys. Acta, 1761:1351.
6. Karasawa, K. (2006) Biochim. Biophys. Acta, 1761:1359.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for PLA2G7/PAF-AH/Lp-PLA2 Antibody (AF5106)(1)

Publication using AF5106

• L Jackisch, W Kumsaiyai, JD Moore, N Al-Daghri, I Kyrou, TM Barber, H Randeva, S Kumar, G Tripathi, PG McTernan Differential expression of Lp-PLA2 in obesity and type 2 diabetes and the influence of lipids Diabetologia, 2018-02-09;0(0):. 2018-02-09 [PMID: 29427237] (IHC, Western Blot, Human)

Bioinformatics

• Gene Symbol: PLA2G7
• Uniprot:
  • AAH38452()